The free/total (F/T) prostate-specific antigen (PSA) ratio is probably the most promising tool proposed to increase the specificity of PSA in the diagnosis of prostate cancer. The aim of the present study was to evaluate the clinical value of the F/T ratio in 138 patients with benign hyperplasia, 101 with untreated prostate cancer, and 176 apparently healthy men.
Methods
We used a new immunometric assay of free PSA (FPSA-RIACT, CIS Diagnostici, Italy) which has shown good analytical performance; sample handling and storage under routine conditions did not affect the antigen stability.
Results
The diagnostic efficiency of the F/T ratio was significantly better than that of total PSA. In patients with total PSA ranging from 4 to 10 ng/ml, at a specificity level of 95% total PSA showed a sensitivity of 7%, whereas the sensitivity of F/T increased to 70%. Using the F/T ratio as a decision tool in association with total PSA and considering all cases candidate to biopsy (total PSA greater than 3.79 ng/ml corresponding to the 95% level), we demonstrated a 35% reduction of total biopsies that would have been required on the basis of total PSA alone.
Conclusions
The determination of the percentage of F/T serum PSA significantly improves the specificity of the marker, particularly in the 4-10 ng/ml dose range where unnecessary prostate biopsies can be reduced.
BabaianR.J., MettlinC., KaneR., MurphyG.P., LeeF., DragoJ.R.: The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography: findings of the American Cancer National Prostate Cancer Detection Project.Cancer, 69: 1195–1200, 1992.
2.
BangmaC.H., HopW.C.J., SchroderF.H.: Serial prostate specific antigen measurements and progression in untreated confined (stages TO to 3NxM0, grades 1 to 3) carcinoma of the prostate.J. Urol., 154: 1403–1406, 1995.
3.
BarichelloM., GionM., Santucci delli PontiU., BolganA., ContemoriG.P., BarioliP., CapitanioG., PecoriB., OmaciniS., BenvegnùL., PetraccoS.: Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.Eur. Urol., 27: 295–300, 1995.
4.
BensonM.C., WhangI.S., PantuckA.: Prostate specific antigen density: means of distinguishing benign prostatic hypertrophy in prostate cancer.J. Urol., 147: 815–816, 1992.
5.
BluesteinD.L., BostwichD.G., BergstralhE.J., OesterlingJ.E.: Eliminating the need for bilateral pelvic lymphadenecto-my in selected patients with prostate cancer.J. Urol., 151: 1315–1320, 1994.
6.
BrawerM.K., ChetnerM.P., BeatieJ., BuchnerD.M., Vessel-laR.L., LangeP.H.: Screening for prostatic carcinoma with prostate specific antigen.J. Urol., 147: 8341–845, 1992.
7.
BrawerM.K.: How to use PSA in early detection or screening for prostatic carcinoma. CA Cancer J.Clin., 45: 148–164, 1995.
8.
CarterH., PearsonJ., MetterE., BrantL.J., ChanD.W., AndresR., FozardJ.L., WalshP.C.: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostatic disease.JAMA, 267: 2215–2220, 1992.
9.
CatalonaW.J., SmithD.S., WolfertR.L., WangT.J., RittenhouseH.G., RatliffT.L., NadlerR.B.: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.JAMA, 274: 1214–1220, 1995.
10.
ChenY.T., LudererA.A., ThielR.P., CarlsonG., CunyC.L., SorianoT.F.: Using proportions of free to total prostate-specific antigen to predict the probability of prostate cancer.Urology, 47: 518–524, 1996.
11.
ChristenssonA., BjorkT., NilssonO., DahlénU., MatikainenT., CockettT.K., AbrahamssonP., LiljaH.: Serum prostate-specific antigen complexed to alpha-1-antichymotrypsin as an indicator of prostate cancer.J. Urol., 150: 100–105, 1993.
12.
ChristenssonA., LaurellC.B., LiljaM.: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors.Eur. J. Biochem., 194: 755–763, 1990.
13.
CooksonM.S., FloydM.K., BallT.P., MillerE.K., SarosdyM.F.: The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels.J. Urol., 154: 1070–1073, 1995.
14.
D'AmicoA.V., WhittingtonR., MalkowiczS.B., SchultzD., SchnallM., TomaszewskiJ.E., WeinA.: A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer.J. Urol., 154: 131–138, 1995.
15.
DavidsonP.J.T., HopW., KurthK.H., FossaS.D., WaehreH., SchroderF.H.: Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stages TO to 4, N1 to 3, M0, D1).J. Urol., 154: 2118–2122, 1995.
16.
FowlerJ.E., PrabhakarP., SeaverL.E., FelizT.P., BraswellN.T.: Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer.J. Urol., 153: 1860–1865, 1995.
17.
HancockS.L., CoxR.S., BagshawM.A.: Prostate specific antigen after radiotherapy for prostate cancer: a reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford university.J. Urol., 154: 1412–1417, 1995.
18.
HuberP.R., SchmidH.P., MattarelliG., StrittmatterB., Van-steenbruggeG.J., MaurerA.: Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate.Prostate, 27: 212–219, 1995.
19.
HudsonM.A., BanhsonR.R., CatalonaW.J.: Clinical use of prostate specific antigen in patients with prostate cancer.J. Urol., 142: 1011–1017, 1989.
20.
HumphreyP.A., KeetchD.W., SmithD.S., ShepherdD.L., CatalonaW.J.: Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening.J. Urol., 155: 816–820, 1996.
21.
KadmonD., WeinbergA.D., WilliamsR.H., PavlikV., CooperP., MiglioreP.J.: Pitfalls in interpreting prostate specific antigen velocity.J. Urol., 155: 1655–1657, 1996.
22.
LeinonenJ., LovgrenT., VornanenT., StenmanU.H.: Double-label time resolved immunofluorometric assay of prostate specific antigen and its complex of prostate specific antigen with alpha-1-antichymotrypsin.Clin. Chem., 39: 2098–2103, 1993.
23.
LiljaM., ChristenssonA., DahlénU., MatikainenM.T., NilssonO., PetterssonK., LövgrenT.: Prostate-specific antigen in serum occurs predominantly in complex with alpha-1-antichymotrypsin.Clin. Chem., 37: 1618–1625, 1991.
24.
McCormackR.T., RittenhouseH.G., FinlayJ.A., SokoloffJ.A., WangT.J., WolfertR.L., LiljaH., OesterlingJ.E.: Molecular forms of prostate-specific antigen and the human kal-likrein gene family: a new era.Urology, 45: 729–744, 1995.
25.
MitrunenK., PetterssonK., PiironenT., BjorkT., LiljaH., LövgrenT.: Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum.Clin. Chem., 41: 1115–1120, 1995.
26.
NadlerR.B., HumphreyP.A., SmithD.S., CatalonaW.J., RatliffT.L.: Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels.J. Urol., 154: 407–413, 1995.
27.
OesterlingJ.E.: Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Significant economic implications.Urol. Clin. North. Am., 20: 705–711, 1993.
28.
OesterlingJ.E., JacobsenS.J., KleeG.G., PettersonK., PiironenT., AbrahamssonP., StenmanU., DowellB., LövgrenT., LiljaH: Free, complexed and total serum prostate specific antigen: establishment of appropriate reference ranges for their concentrations and ratios.J. Urol., 154: 1090–1095, 1995.
29.
PartinA.W., YooJ., CarterJ.B., PearsonJ.D., ChanD.W., EpsteinJ.I., WalshP.C.: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.J. Urol., 150: 110–114, 1993.
30.
PausE., FossaD., NilssonO., EriM.: The ratio of free to total PSA may be influenced by handling of serum samples.Anticancer Res., 15: 2402, 1995.
31.
RaveryV., De la TailleA., ToublancM., Boccon-GibodL., HermieuJ.F., DelmasV., Boccon-GibodL.: Prostate specimen reevaluation in patients with organ confined prostate cancer and postoperative biological recurrence.J. Urol., 155: 1981–1982, 1996.
32.
RavivG., ZlottaA.R., JanssenT., DescampsF., VanegasJ.P., VehrestA., SchulmanC.C.: Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma?Cancer, 77: 2103–2106, 1996.
33.
RosenzweigK.E., MorganW.R., LyttonB., PeschelR.E.: Prostate specific antigen following radiotherapy for local prostate cancer.J. Urol., 153: 1561–1564, 1995.
34.
RuckleH.C., KleeG.G., OesterlingJ.E.: Prostate specific antigen: critical issues for the practicing physician.Mayo Clin. Proc., 69: 59–68, 1994.
35.
RuckleH.C., KleeG.G., OesterlingJ.E.: Prostate specific antigen: concepts for staging prostate cancer and monitoring response to therapy.Mayo Clin. Proc., 69: 69–79, 1994.
36.
StameyT.A.: Second Stanford conference on International standardization of prostate-specific antigen immunoassays.Urology, 45: 173–184, 1995.
37.
StenmanU.M., LeinonenJ., AlfthanH., RannikkoS., TuhkanenK., AlfthanO.: A complex between prostate-specific antigen and gamma-1-antichymotrypsin is a major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.Cancer Res., 51: 222–226, 1991.
38.
WoodrumD., FrenchC., ShamelM., RomanS.: Stability of free PSA in serum.J. Urol., 155: 421, 1996.
